Skip to main content
Premium Trial:

Request an Annual Quote

Affy Shares Up 6.4 Percent Two Days After Upgrade by Cairns

NEW YORK, March 24 (GenomeWeb News) - Shares in Affymetrix were up 6.4 percent since since Tuesday's closing price after an analyst for Cairns & Company yesterday raised the stock to "Above Average" from a "Buy." 

 

Shares in the world's largest microarray maker were trading at $44.48 in mid-afternoon today, up from $41.79 the day before the analyst upgraded the stock.

 

The Cairns move comes six days after Thomas Weisel upgaded the shares to "Outperform" from "Peer Perform." The company's stock has since risen $4.84, or 12.2 percent, from its closing price of $39.74 the day before Thomas Weisel's upgrade.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.